Dynorphin A increases substance P release from trigeminal primary afferent C-fibers.

Dynorphin A-(1-17) has been found to produce spinal antianalgesia and allodynia. Thus, we studied whether dynorphin A-(1-17) modulates substance P release evoked by the C-fiber-selective stimulant capsaicin (1 microM) from trigeminal nucleus caudalis slices. Very low concentrations of dynorphin A-(1-17) (0.01-0.1 nM) strongly facilitated capsaicin-evoked substance P release. This dynorphin A-(1-17) effect was not blocked by the opioid receptor antagonists naloxone (100 nM), beta-funaltrexamine (20 nM), naloxonazine (1 nM), nor-binaltorphimine (3 nM) and ICI 174,864 (N,N-dialyl-Tyr-Aib-Phe-Leu; 0.3 microM). Yet, the effect of dynorphin A-(1-17) was blocked by the NMDA receptor antagonist MK-801 ((+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d] cyclohepten-5-10-imine maleate; 0.3 microM). Neonatal treatment with capsaicin (50 mg/kg s.c.), which destroys substance P-containing primary afferents, abolished the excitatory effect of dynorphin A-(1-17) on K+-evoked substance P release. In conclusion, dynorphin A-(1-17) increases substance P release from C-fibers by the activation of NMDA receptors which supports the involvement of presynaptic mechanisms in dynorphin-induced antianalgesia and allodynia.

A highly selective assay for neutral endopeptidase based on the cleavage of a fluorogenic substrate related to Leu-enkephalin.

An intramolecularly quenched fluorogenic peptide structurally related to Leu-enkephalin, containing o-aminobenzoyl (Abz) and ethylenediamine 2,4-dinitrophenyl (EDDnp) groups at amino- and carboxyl-terminal amino acid residues, Abz-Gly-Gly-D-Phe-Leu-Arg-Arg-Val-EDDnp (Abz-GGDFLRRV-EDDnp), was selectively hydrolyzed at the Arg-Val bond by neutral endopeptidase (NEP, enkephalinase, neprilysin, EC 3.4.24.11) with kinetic parameters (Km = 3 microM, kcat = 127 min-1 and kcatsolidusKm = 42 min-1 microM-1) similar to those of the Leu-enkephalin. The specificity of the NEP assay was demonstrated by incubating Abz-GGDFLRRV-EDDnp with a kidney homogenate or with crude membrane preparations of brain and lung: more than 95% of all products released were the complementary fragments Abz-GGDFLRR and V-EDDnp which were totally inhibited by 1 microM thiorphan, a highly specific NEP inhibitor. The blocked amino- and carboxyl-terminal amino acids protected this substrate against the action of aminopeptidases as well as of carboxypeptidases. Furthermore, D-Phe amino acid also ensured a very good protection of Abz-GGDFLRRV-EDDnp against the action of other tissue endopeptidases distinct from NEP. A continuous fluorometric assay for only 5 min was sufficient to quantify the NEP activity with a minimum sensitivity of 5 ng of purified enzyme or the equivalent enzymatic activity in crude tissue preparations. Therefore, amounts as little as 0.5 ng of enzyme could be quantified employing longer times of incubation.

[Role of nitric oxide in alterations of the systemic and splanchnic hemodynamics in a experimental model of portal hypertension]. / Papel del óxido nítrico en las alteraciones de la hemodinámica sistémica y esplácnica en un modelo experimental de hipertensión portal.

Recent experimental studies have suggested that an increase in the synthesis of nitric oxide, a powerful vasodilator secreted by endothelial cells, plays a role in the hemodynamic disturbances associated to portal hypertension. The present study was addressed to investigate the effects of L-NNA (a specific inhibitor of nitric oxide) on systemic and splanchnic hemodynamics in portal hypertensive rats, induced by partial portal vein ligation. Intravenous infusion of L-NNA (50 ug/kg/min) significantly increased systemic blood pressure and decreased cardiac output as measured by radiolabeled microspheres. A significant increase in systemic and splanchnic vascular resistance was also observed in L-NNA-treated rats; whereas portal blood flow decreased significantly, L-NNA did not modify portal pressure. Pretreatment with L-arginine (300 mg/Kg, i.v.) prevented the hemodynamic changes induced by L-NNA. Similar values of endotoxin levels were detected in both groups of animals. In the control group, L-NNA caused a mild but significant increase of mean arterial pressure; no significant changes on the other hemodynamic parameters were observed. These results suggest that an increase in endogenous synthesis of nitric oxide may play an important role in hemodynamic disturbances associated with chronic portal hypertension.

Papel del óxido nítrico en las alteraciones de la hemodinámica sistémica y esplácnica en un modelo experimental de hipertensión portal / Role of nitric oxide in the alterations of the systemic and splanchnic hemodynamics in a experimental model of portal hypertension

Se evaluó el efecto de la Nw-Nitro-L-arginina (L-NNA), un inhibidor específico de la síntesis de óxido nítrico, sobre la hemodinámica sistémica y esplácnica en un modelo experimental de hipertensión portal (ligadura parcial de la vena porta). La administración de L-NNA en los animales con hipertensión portal ocasionó un aumento significativo de la presión arterial media, una reducción del gasto cardíaco y un aumento de la resistencia vascular periférica. A nível de la hemodinámica esplácnica la L-NNA ocasionó un marcado incremento de la resistencia vascular esplácnica con la consecuente disminución del flujo sanguíneo portal. No se observaron cambios singnificativos en la presión portal. El pretratamiento con L-arginina inhibió los efectos hemodinámicos de la L-NNA. Similares niveles plasmáticos de endotoxina se detectaron en ambos grupos de animales. En el grupo control La L-NNA produjo un aumento de la presión arterial media; sin embargo, y a diferencia de lo observado en los animales on hipertensión portal, la administración de L-NNA no se acompaño de cambios significativos en el gasto cardíaco, flujo sanguíneo portal ni resistencia vascular esplácnica. Nuestros resultados sugieren que las alteraciones, tanto de la hemodinámica sistémica como esplácnica, asociadas a la hipertensión portal, pueden ser atenuadas mediante la administración de L-NNA. Asimismo, el aumento de la síntesis de óxido nítrico puede jugar un papel importante en la fisiopatogenia de estos trastornos hemodinámicos

Papel del óxido nítrico en las alteraciones de la hemodinámica sistémica y esplácnica en un modelo experimental de hipertensión portal / Role of nitric oxide in the alterations of the systemic and splanchnic hemodynamics in a experimental model of portal hypertension

Se evaluó el efecto de la Nw-Nitro-L-arginina (L-NNA), un inhibidor específico de la síntesis de óxido nítrico, sobre la hemodinámica sistémica y esplácnica en un modelo experimental de hipertensión portal (ligadura parcial de la vena porta). La administración de L-NNA en los animales con hipertensión portal ocasionó un aumento significativo de la presión arterial media, una reducción del gasto cardíaco y un aumento de la resistencia vascular periférica. A nível de la hemodinámica esplácnica la L-NNA ocasionó un marcado incremento de la resistencia vascular esplácnica con la consecuente disminución del flujo sanguíneo portal. No se observaron cambios singnificativos en la presión portal. El pretratamiento con L-arginina inhibió los efectos hemodinámicos de la L-NNA. Similares niveles plasmáticos de endotoxina se detectaron en ambos grupos de animales. En el grupo control La L-NNA produjo un aumento de la presión arterial media; sin embargo, y a diferencia de lo observado en los animales on hipertensión portal, la administración de L-NNA no se acompaño de cambios significativos en el gasto cardíaco, flujo sanguíneo portal ni resistencia vascular esplácnica. Nuestros resultados sugieren que las alteraciones, tanto de la hemodinámica sistémica como esplácnica, asociadas a la hipertensión portal, pueden ser atenuadas mediante la administración de L-NNA. Asimismo, el aumento de la síntesis de óxido nítrico puede jugar un papel importante en la fisiopatogenia de estos trastornos hemodinámicos (AU)